Abstract
Reduced cardiac mass and performances are present in GH deficiency and are coun-teracted by rhGH replacement. GH and IGF-I possess specific myocardial receptors and have been reported able to exert an acute inotropic effect. Synthetic GH secretagogues (GHS) possess specific pituitary and hypothalamic but even myocar-dial receptors. In 7 male volunteers, we studied cardiac performance by radionuclide angiocardiography after iv administration of rhGH or hexare-lin (HEX), a peptidyl GHS. The administration of rhGH or HEX increased circulating GH levels to the same extent (AUC: 1594.6±88.1 vs 1739.3±262.2 μg/l/min for 90 min) while aldosterone and cate-cholamine levels did not change; HEX, but not rhGH, significantly increased cortisol levels. Left ventricular ejection fraction (LVEF), mean blood pressure (MBP) and heart rate (HR) were unaffected by rhGH (62.4±2.1 vs 62.1±2.3%, 90.6±3.4 vs 92.0±2.5 mm Hg, 62.3±1.8 vs 66.7±2.7 bpm). HEX increased LVEF (70.7±3.0 vs 64.0±1.5%, p<0.03) without significant changes in MBP and HR (92.8±4.7 vs 92.4±3.2 mmHg, 63.1±2.1 vs 67.0±2.9 bpm). LVEF significantly raised at 15 min, peaked at 30 min and lasted up to 60 min after HEX. These findings suggest that in man, the acute administration of Hexarelin exerts a short-lasting, positive inotropic effect. This effect seems GH-in-dependent and might be mediated by specific GHS myocardial receptors.
Similar content being viewed by others
References
Saccà L., Cittadini A., Fazio S. Growth hormone and the heart. Endocr. Rev. 1994, 15: 555–573.
Donath M.Y., Zapf J., Eppenberger-Eberhardt M., Froesch E.R., Eppenberger H.M. Insulin-like growth factor I stimulates myofibril development and decreases smooth muscle-actin of adult cardiomyocytes. Proc. Natl. Acad. Sci. 1994, 91: 1686–1690.
Isgaard J., Kujacic V., Jennische E., Holmang A., Sun X.Y., Hedner T., Hialmarson A., Bengtsson B.A. Growth hormone improves cardiac function in rats with experimental myocardial infarction. Eur. J. Clin. Invest. 1997, 27: 517–525.
Duerr R.L., Huang S., Miraliakbar H.R., Clark R., Chien K.R., Ross J. Insulin-like Growth Factor-I enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J. Clin. Invest. 1997, 95: 619–627.
Cittadini A., Stromer H., Katz S.E., Katz S.E., Clark R., Moses A.C., Morgan J.P., Douglas P.S. Differential cardiac effects of growth hormone and insulin-like growth factor I in the rat. A combined in vivo and in vitro evaluation. Circulation 1996, 93: 800–809.
Yang R., Bunting S., Gillett N., Clark R., Jin H. Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995, 92: 262–267.
Shahi M., Beshyah S.A., Hackett D., Sharp P.S., Johnston D.G., Foale R.A. Myocardial dysfunction in treated adult hypopitu-itarism: a possible explanation for increased cardiovascular mortality. Br. Heart J. 1992, 67: 92–96.
Amato G., Carella C., Fazio S., La Montagna G., Cittadini A., Sabatini D., Marciano-Mone C., Saccà L., Bellastella A. Body composition, bone metabolism and heart structure and function in Growth Hormone (GH) deficient adults before and after GH replacement therapy at low doses. J. Clin. Endocrinol. Metab. 1993, 177: 1671–1676.
Merola B., Cittadini A., Colao A., Longobardi S., Fazio S., Sabatini D., Saccà L., Lombardi G. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J. Clin. Endocrinol. Metab. 1993, 177: 1658–1661.
Salomon F., Cuneo R.C., Hesp R., Sonksen P. The effect of treatment with recombinant human growth hormone on body composition and metabolism in adult with growth hormone deficiency. N. Engl. J. Med. 1989, 321: 1797–1803.
Duerr R.L., McKirnan M.D., Gim R.D., Clark R.G., Kien K.R., Ross J. Jr. Cardiovascular effects of Insulin-like Growth Factor I and growth hormone in chronic left ventricular failure in the rat. Circulation 1996, 93: 2188–2196.
Fazio S., Sabatini D., Capaldo B., Vigorito C., Giordano A., Guida R., Pardo F., Biondi B., Saccà L. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N. Engl. J. Med. 1996, 334: 809–814.
Osterziel K.J., Strohm O., Schuler J., Friedrich M., Hanlen D., Willenbrock R., Anker S.D., Poole-Wilson P.A., Ranke M.B., Dietz R. Randomized, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyo-pathy. Lancet 1998, 51: 1233–1237.
Volterrani M., Desenzani P., Lorusso R., d’Aloia A., Manelli F., Giustina A. Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet 1991, 359: 1067–1068.
Donath M.Y., Jenni R., Brunner H.P., Anrig M., Kohli S., Glatz Y., Froesch E.R. Cardiovascular and metabolic effects of Insulin-like Growth Factor-I at rest and during exercise in humans. J. Clin. Endocrinol. Metabl 1996, 81: 4089–4094.
Donath M.Y., Sutsch G., Yan X.W., Piva B., Brunner H.P., Glatz Y., Glatz Y., Zpaf J., Follath F., Froesch E.R., Kiowski W. Acute cardiovascular effects of Insulin-Like Growth Factor I in patients with chronic heart failure. J. Clin. Endocrinol. Metab. 1998, 83: 3177–3183.
Russel-Jones D.L., Bates A.T., Umpleby A.M., Hennessy T.R., Bowes S.B., Hopkins K.D., Jackson N., Kelly J., Shojaee-Moradie F., Jones R.H., Sonksen P.H. A comparison of the effects of IGF-I and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteers. Eur. J. Clin. Invest. 1995, 25: 403–411.
Bowers C.Y., Veeraragavan K., Sethumadhavan K. Atypical growth hormone releasing peptides. In: Bercu B.B., Walker R.F. (Eds.), Growth hormone II, basic and clinical aspects. Springer-Verlag, New York, 1993, pp. 203–222.
Ghigo E., Arvat E., Muccioli G., Camanni F. Growth hormone-releasing peptides. Eur. J. Endocrinol. 1997, 136: 445–460.
Smith R.G., Van der Ploeg L.X.T., Howard A.D., Feighner S.D., Chang K., Hickey G.J., Wyvratt M.J., Fisher M.H., Nargunt R.P., Patchett A.A. Peptidomimetic regulation of growth hormone secretion. Endocr. Rev. 1997, 18: 621–645.
Arvat E., Di Vito L., Maccagno B., Broglio F., Boghen M.F., Deghenghi R., Camanni F., Ghigo E. Effects of GHRP-2 and Hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol level in man. Comparison with the effects of GHRH, TRH, and hCRH. Peptides 1997, 18: 885–891.
Arvat E., Di Vito L., Lanfranco F., Broglio F., Giordano R., Benso A., Muccioli G., Deghenghi R., Ghigo E. Tyr-Ala-Hexarelin, a synthetic octapetide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans. J. Endocrinol. Invest. 1999, 22: 91, in press.
Arvat E., Maccagno B., Ramunni J., Broglio F., Lanfranco F., Giordano R., Benso A., Deghenghi R., Ghigo E. Influence of galanin and serotonin on the endocrine response to Hexarelin, a peptidyl GH-secretagogue, In normal women. J. Endocrinol. Invest. 1998, 21: 673–679.
Howard A.D., Feighner S.D., Cully D.F., Arena J.P., Liberator P.A., Rosenblum C., Uamelin M., Ureniuk D.I., Palyme O.C., Anderson J., Paress P.S., Diaz C., Choun Liu K.K., Pong S.S., Cheung L.Y., Elbrecht A., Dashkeiviez M., Keavens R., Rishy M., Siringjhsinghji D.I.S., Dean D.C., Melillo D.G., Patchett A.A., Nergund R., Srillin P.R. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996, 273: 974–977.
Ong H., McNicoll N., Esden E., Collu R., Deghenghi R., Locatelli V., Ghigo E., Muccioli G., Boghen M.F., Nillson M.H.L. Identification of a pituitary GHRP receptor subtype by the photoaffinity labeling approach using a [125I]p-ben-zoyl-phenylalanine Hexarelin derivative. Endocrinology 1998, 739: 432–435.
Muccioli G., Ghe C., Ghigo M.C., Arvat E., Papotti M., Boghen M.F., Nillsson M., Deghenghi R., Ong H., Ghigo E. GHRP receptors in pituitary, central nervous system and peripheral human tissues. Proc XXVII National Congress of the Italian Society of Endocrinology, Sorrento, Italy, 1997. J. Endocrinol. Invest. 1997, 20 (Suppl. 4): 52 (Abs.).
Muccioli G., Ghè C., Papotti M, Boghen M.F., Nillson M., Deghenghi R., Ong H., Ghigo E. Tissue distribution of GHRP receptors in humans. Proc IV European Congress of Endocrinology, Sevilla, Spain, 9–13 May 1998. OR 15–7 (Abs.).
Bodart V., McNicoll N., Carriere P., Bouchard J.F., Lamontagne D., Sejlitz T., Ong H. Identification and characterization of a new GHRP receptor in the heart. Proc 80th Annual Meeting of the Endocrine Society, New Orleans, Louisiana, June 24–24th 1998, P2–239 (Abstract).
Ong H., Bodart V., Mc Nicoll N., Lamontagne D., Bouchard J.F. Binding siteds for growth hormone-releasing peptide. GH and IGF-I Research 1998, 8: 137–143.
Guan X.M., Yu H., Palyha O.C., McKee K.K., Feighner S.D., Sirinathsinhji D.J.S., Smith R.G., Van der Ploeg L.H.T., Howard A.D. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Mol. Brain Res. 1998, 48: 23–29.
De Gennaro Colonna V., Rossoni G., Bernareggi M., Muller E.E., Berti F. Cardiac ischemia and impairment of vascular en-dothelium function in hearts from GH-deficient rats: protection by hexarelin. Eur. J. Pharmacol. 1997, 34: 201–207.
Rossoni G., De Gennaro Colonna V., Bernareggi M., Polvani G.L., Muller E.E., Berti F. Protectant activity of Hexarelin or growth hormone against post-ischemic ventricular dysfunction in hearts from aged rats. J. Cardiovas. Pharmacol. 1998, in press.
Berti F., Muller E.E., De Gennaro Colonna V., Rossoni G. Hexarelin exibits protective activity against cardiac ischaemia in hearts from growth hormone-deficient rats. GH and IGF-I Research 1998, 8: 149–155.
Isgaard J., Tivesten A., Bollano E., Kujacic V., Caidahl K., Sun X.Y., Hedner T., Hjalmarson A., Bengtsson B.A. The growth hormone secretagogue Hexarelin improves cardiac function in rats after experimental myocardial infarction. Proc. IV European Congress of Endocrinology, Sevilla, Spain, 9–13 May 1998; OR 3–7 (Abs.).
Links J.M., Becker L.C., Shindledecker J.G., Guzman P., Burow R.D., Nickoloff E.L., Alderson P.O., Wagner H.N. Measurement of absolute left ventricular volume from gated blood pool studies. Circulation 1982, 65: 82–91.
De Gennaro Colonna V., Rossoni G., Bonacci D., Ciceri S., Cattaneo L., Muller E.E., Berti F. Worsening of ischemic damage in hearts from rats with selective growth hormone deficiency. Eur. J. Pharmacol. 1996, 14: 333–338.
Muller E.E., Nistico G. Neurotransmitter regulation of the anterior pituitary. In: Muller E.E., Nisticò G. (Eds.), Brain messengers and the pituitary. Academic Press, San Diego, 1989, pp. 404–537.
Heldwein K.A., Redick D.L., Rittenberg M.B., Claycomb W.C., Stenzel-Poore M.P. Corticotropin-releasing hormone receptor expression and functional coupling in neonatal cardiac myo-cytes and AT-I cells. Endocrinology 1996, 137: 3631–3639.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bisi, G., Podio, V., Valetto, M.R. et al. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. J Endocrinol Invest 22, 266–272 (1999). https://doi.org/10.1007/BF03343555
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343555